In this review, the authors review data on disease burden and transplant outcomes in myelodysplastic syndromes (MDS), and describe which MDS patients may benefit most from allogeneic hematopoietic cell transplantation (HCT). They outline the optimal timing for HCT and recommend early transplantation of patients with IPSS or IPSS-R higher-risk disease, with a hypomethylating agent as a bridge to transplant for patients who may not find a donor quickly. The authors also recommend that patients with more than 10% blasts be considered for cytoreductive therapy before transplant, especially if reduced-intensity conditioning HCT is planned.
Brierley CK, et al. Curr Opin Hematol